RAPT Therapeutics Reports First Quarter 2022 Financial Results Portfolio News / By Karina Tin May 11, 2022 RAPT Therapeutics Reports First Quarter 2022 Financial Results Read More »
Surrozen Reports First Quarter 2022 Financial Results Portfolio News / By Karina Tin May 11, 2022 Surrozen Reports First Quarter 2022 Financial Results Read More »
eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin May 10, 2022 eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Read More »
Nurix Therapeutics to Host R&D Day on May 26, 2022 Portfolio News / By Karina Tin May 9, 2022 Nurix Therapeutics to Host R&D Day on May 26, 2022 Read More »
ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update Portfolio News / By Karina Tin May 9, 2022 ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update Read More »
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin May 9, 2022 Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress Read More »
NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results Portfolio News / By Karina Tin May 5, 2022 NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results Read More »
RAPT Therapeutics Expands Leadership Team with Multiple Key Hires Portfolio News / By Karina Tin May 4, 2022 RAPT Therapeutics Expands Leadership Team with Multiple Key Hires Read More »
Plexium Appoints Stephen Mullennix as Chief Financial Officer Portfolio News / By Karina Tin May 3, 2022 Plexium Appoints Stephen Mullennix as Chief Financial Officer Read More »
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Portfolio News / By Karina Tin May 2, 2022 Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Read More »
